Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Gliptus vs Galvus (Vildagliptin) in Healthy Volunteers
NCT02816970Phase 1Completed
- Sponsor
- Genuine Research Center
- Start
- Feb 2014
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vildagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Genuine Research Center. Primary endpoints: Maximal measured plasma concentration at 24 hours, Area under the plasma concentration-time curve from time zero to time t at 24 hours and 1 more. Started Feb 2014; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02816970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02816970.